The person who posted that Titanic message has the attitude that Amarin is racing to bankruptcy and all investors will lose everything. But that's highly unlikely to be the case. In fact, the company was managing to stay afloat and lose very little each quarter until last quarter. And it does seem to be taking drastic action with the further staffing reduction and $100 million slashing of expenses.
At some point, some revenue will begin trickling in from the launch of sales in multiple European countries and we will get a clearer idea of what the potential is.
The best chances for a decent catalyst, I think, are:
1) Real sales in European countries
2) Any kind of partnership with Big Pharma akin to what Pfizer is doing for Vascepa in Canada.
3) Positive results in the Alzheimer's trial slated to end in February. I know it's a small study of only about 150 people, but it takes very little in that area to create great interest. Just look at SAVA and AVXL. I don't hold out great hope for this trial though since the end date was already extended by 15 months. That tells me that they're probably having trouble seeing significant results and are hoping that a wider window improves the chances of measurable results.